Reprint: Good laboratory practice: preventing introduction of bias at the bench

Area of Science:

• Neuroscience
• Translational Medicine
• Pharmacology

Background:

• Drugs demonstrating efficacy in animal models of cerebral ischemia often fail in human stroke trials.
• This translational gap may stem from systematic bias in preclinical animal studies, overstating drug efficacy.
• Problems in study design, conduct, and reporting contribute to inflated neuroprotection results.

Purpose of the Study:

• To identify and address systematic biases in animal experiments modeling human stroke.
• To propose concrete measures for improving the design, conduct, and reporting of preclinical stroke research.
• To enhance the reliability of animal models for evaluating potential neuroprotective therapies.

Main Methods:

• Review of existing literature on bias in preclinical stroke research.
• Development of a framework for bias reduction in animal experiment design.
• Recommendations for standardized conduct and transparent reporting of experimental data.

Main Results:

• Identification of key sources of bias, including inadequate randomization, blinding, and outcome reporting.
• A comprehensive set of guidelines to mitigate bias in animal stroke models.
• Emphasis on reproducible research practices to improve translation to clinical settings.

Conclusions:

• Addressing bias in animal experimental design is crucial for successful translation of stroke therapies.
• Implementing proposed measures can increase the predictive validity of animal models for human stroke.
• Improved preclinical research standards are essential for advancing neuroprotection strategies and improving patient outcomes.